Nova Eye Medical Limited (ASX:EYE)

Australia · Delayed Price · Currency is AUD

0.1600

+0.0100 (6.67%)

Oct 27, 2026, 2:15 PM AEDT

Market Cap	45.59M +0.0%
Revenue (ttm)	34.87M +19.1%
Net Income	-4.33M
EPS	-0.02
Shares Out	284.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	900,566
Open	0.1500
Previous Close	0.1500
Day's Range	0.1500 - 0.1650
52-Week Range	0.1000 - 0.2050
Beta	0.93
Analysts	Buy
Price Target	0.43 (+168.75%)
Earnings Date	Nov 1, 2026

About Nova Eye Medical

Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. The company operates through Glaucoma Surgical Devices and AlphaRET segments. It offers 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degeneration for the treatment of retinal disease. The company offers iTrack, a glaucoma surgical device to reduce intraocular pressure in patients glaucoma; ... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 1970

Employees 301

Stock Exchange Australian Securities Exchange

Ticker Symbol EYE

Full Company Profile

Financial Performance

In fiscal year 2026, Nova Eye Medical's revenue was 34.87 million, an increase of 19.13% compared to the previous year's 29.27 million. Losses were -4.33 million, -52.17% less than in 2025.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for EYE stock is "Buy." The 12-month stock price target is $0.43, which is an increase of 168.75% from the latest price.

Price Target

$0.43

(168.75% upside)

Analyst Consensus: Buy

Stock Forecasts